RCKTのチャート
RCKTの企業情報
| symbol | RCKT |
|---|---|
| 会社名 | Rocket Pharmaceuticals Inc （イノテック・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Rocket Pharmaceuticals Inc. formerly Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate trabodenoson is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye''s natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye''s trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation as well as a fixed-dose combination (FDC) of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases. イノテック・ファ―マシュ―ティカルズは米国の臨床段階のバイオ医薬品会社。緑内障の治療法の発見、開発、商業化に焦点を当てる。同社の点眼製剤Trabodenosonは、圧力制御機構を復元することによって、眼圧を低下させるように設計され、1日1回の投与療法で使用される。 Rocket Pharmaceuticals, Inc. is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The Company's platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia, and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. Rocket's first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. |
| 本社所在地 | 350 Fifth Avenue Suite 7530 New York NY 10118 USA |
| 代表者氏名 | J. Martin Carroll J.マーティンキャロル |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 646-440-9100 |
| 設立年月日 | 36342 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 20人 |
| url | www.inotekpharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/rckt |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -39.95900 |
| 終値（lastsale） | 20.85 |
| 時価総額（marketcap） | 826929639.9 |
| 時価総額 | 時価総額（百万ドル） 745.22820 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 652.96720 |
| 当期純利益 | 当期純利益（百万ドル） -43.37500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Rocket Pharmaceuticals Inc revenues was not reported. Net loss increased from $6.2M to $31.1M. Higher net loss reflects Research and development - Balancing val increase from $5M to $12.9M (expense) General and administrative - Balancing v increase from $1.2M to $8.2M (expense) Stock-based Compensation in SGA increase from $108K to $4.6M (expense). |
RCKTのテクニカル分析
RCKTのニュース
Rocket Pharmaceuticals Inc. (RCKT) did well last session? 2023/03/01 12:16:00 US Post News
As of Tuesday, Rocket Pharmaceuticals Inc.’s (NASDAQ:RCKT) stock closed at $19.21, up from $18.46 the previous day. While Rocket Pharmaceuticals Inc. has overperformed by 4.06%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RCKT rose by 7.62%, with highs and lows ranging from $23.48 to $7.57, […]
Rocket Pharma COO On Observing Rare Disease Day, And Why It Deserves US Attention 2023/02/28 19:34:26 Benzinga
Feb. 28 is Rare Disease Day . It''s meant to observe the more than 400 million people globally — 50% of them children — that are affected by rare, pediatric life-threatening diseases such as leukemia, Cystic Fibrosis and Hemophilia to name a few. But for Rocket Pharmaceuticals Inc. (NASDAQ: RCKT ), every day is rare disease day. The biotech firm, which went public in October, is among the most prominent players in the space with six genetic therapies in its pipeline. To learn more about the Cranbury, New Jersey-based company, Benzinga spoke with Rocket Pharma president and COO Kinnari Patel about the firm''s ongoing quest to find gene therapy cures. See Also: Rocket Pharmaceuticals Announces Proposed Public Offering Of $100M Of Shares Of Its Common Stock BZ: When Rare Disease Day was started in 2008, it was intended for Feb. 29 — a rare day that only occurs on leap years — by the European Organisation for Rare Diseases. Does the day get the attention it deserves in the U.S.? Patel : While Rare Disease Day has started to get attention in the U.S., it deserves even more attention, as the unmet needs for the global rare disease community are staggering.
Rocket Pharmaceuticals GAAP EPS of -$0.92 misses by $0.10 2023/02/27 21:36:44 Seeking Alpha
Rocket Pharmaceuticals press release (RCKT): Q4 GAAP EPS of -$0.92 misses by $0.10.Cash, cash equivalents and investments of approximately $400M; expected operational runway through 2024
Rocket Pharmaceuticals: Q4 Earnings Snapshot 2023/02/27 21:15:42 WTOP
CRANBURY, N.J. (AP) — CRANBURY, N.J. (AP) — Rocket Pharmaceuticals Inc. (RCKT) on Monday reported a loss of $66.7 million…
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results 2023/02/27 21:01:00 Business Wire
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and operational results for the fourth quarter and year ended December 31, 2022. “Rocket closed 2022 with positive results across four gene therapy programs spanning both our AAV cardiology and LV hematology therapeutic areas in an unpreceden
Rocket Pharmaceuticals Inc. (RCKT) did well last session? 2023/03/01 12:16:00 US Post News
As of Tuesday, Rocket Pharmaceuticals Inc.’s (NASDAQ:RCKT) stock closed at $19.21, up from $18.46 the previous day. While Rocket Pharmaceuticals Inc. has overperformed by 4.06%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RCKT rose by 7.62%, with highs and lows ranging from $23.48 to $7.57, […]
Rocket Pharma COO On Observing Rare Disease Day, And Why It Deserves US Attention 2023/02/28 19:34:26 Benzinga
Feb. 28 is Rare Disease Day . It''s meant to observe the more than 400 million people globally — 50% of them children — that are affected by rare, pediatric life-threatening diseases such as leukemia, Cystic Fibrosis and Hemophilia to name a few. But for Rocket Pharmaceuticals Inc. (NASDAQ: RCKT ), every day is rare disease day. The biotech firm, which went public in October, is among the most prominent players in the space with six genetic therapies in its pipeline. To learn more about the Cranbury, New Jersey-based company, Benzinga spoke with Rocket Pharma president and COO Kinnari Patel about the firm''s ongoing quest to find gene therapy cures. See Also: Rocket Pharmaceuticals Announces Proposed Public Offering Of $100M Of Shares Of Its Common Stock BZ: When Rare Disease Day was started in 2008, it was intended for Feb. 29 — a rare day that only occurs on leap years — by the European Organisation for Rare Diseases. Does the day get the attention it deserves in the U.S.? Patel : While Rare Disease Day has started to get attention in the U.S., it deserves even more attention, as the unmet needs for the global rare disease community are staggering.
Rocket Pharmaceuticals GAAP EPS of -$0.92 misses by $0.10 2023/02/27 21:36:44 Seeking Alpha
Rocket Pharmaceuticals press release (RCKT): Q4 GAAP EPS of -$0.92 misses by $0.10.Cash, cash equivalents and investments of approximately $400M; expected operational runway through 2024
Rocket Pharmaceuticals: Q4 Earnings Snapshot 2023/02/27 21:15:42 WTOP
CRANBURY, N.J. (AP) — CRANBURY, N.J. (AP) — Rocket Pharmaceuticals Inc. (RCKT) on Monday reported a loss of $66.7 million…
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results 2023/02/27 21:01:00 Business Wire
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and operational results for the fourth quarter and year ended December 31, 2022. “Rocket closed 2022 with positive results across four gene therapy programs spanning both our AAV cardiology and LV hematology therapeutic areas in an unpreceden
Rocket Pharmaceuticals: 2 Regulatory Filings In 2023 Could Propel It Higher (NASDAQ:RCKT) 2022/11/29 15:50:19 Seeking Alpha
A Rocket Pharmaceuticals, Inc. regulatory filing to the FDA of LV RP-L201 for Leukocyte Adhesion Deficiency-I is expected in the 1st half of 2023. Click to learn more.
Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference | MarketScreener 2022/11/21 13:04:02 MarketScreener
Rocket Pharmaceuticals, Inc. , a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need,… | November 21, 2022